← All indications
Osteoarthritis, Hip
Noninflammatory degenerative disease of the hip joint which usually appears in late middle or old age. It is characterized by growth or maturational disturbances in the femoral neck and head, as well as acetabular dysplasia. A dominant symptom is pain on weight-bearing or motion.
Drugs by status
Phase 4 trials (36)
- diclofenac
- propofol
- methylprednisolone
- denosumab
- atracurium
- urea
- cefazolin
- chlorzoxazone
- prednisone
- ibuprofen
- ferric carboxymaltose
- ethanol
- mepivacaine
- human factor ix complex (prothrombin complex concentrate)
- ropivacaine
- lidocaine
- epinephrine
- hyaluronic acid
- levobupivacaine
- celecoxib
- bupivacaine
- clonidine
- enoxaparin
- zoledronic acid
- aminocaproic acid
- nandrolone phenpropionate
- dexmedetomidine
- fentanyl
- rivaroxaban
- tranexamic acid
- +6 more
Phase 3 trials (20)
Phase 2 trials (11)
Phase 1 trials (3)
Organizations
Organization Involved with Phase 4 Indications (27)
- Pfizer
- Novartis
- Gebro Pharma GmbH
- Region Syddanmark
- Rockefeller University
- University of Pittsburgh
- Duke University
- Hospital Mutua de Terrassa
- Rutgers University
- Thomas Jefferson University
- University of Ottawa
- University of Sydney
- Wake Forest University
- Laval University
- The Christ Hospital
- University of Copenhagen
- University of Turku
- Konkuk University
- Chiangmai University
- Rehabilitationszentrum, Bad Hofgastein
- University of New South Wales
- National Health and Medical Research Council, Australia
- Stryker
- Government of Finland
- Sungkyunkwan University
- Medical Benefits Fund Australia Pty Ltd
- Government of Denmark
Organization Involved with Phase 3 Indications (30)
- Regeneron
- Daiichi Sankyo
- McNeil
- Grunenthal
- Merck
- Eli Lilly
- Alza
- Bayer
- CrystalGenomics, Inc.
- Laboratoires Expanscience S.A.
- Laboratoires NEGMA
- Mallinckrodt
- NicOx
- Chang Gung University
- Martina Hansen's Hospital
- Seoul National University
- University Hospital Pellenberg
- University of Oslo
- University of Regensburg
- Mayo Clinic
- CHU Henri Mondor
- Hospital Universitario Virgen Macarena
- Flexion Therapeutics
- Mitsubishi Tanabe
- South-Eastern Norway Regional Health Authority
- Alpharma
- Johnson and Johnson
- Government of Spain
- Alberta Bone and Joint Health Institute
- CAPRI Clinic
Organization Involved with Phase 2 Indications (15)
- Pascoe Pharmazeutische Praeparate GmbH
- Teva
- VivaTech International, Inc.
- United States Navy
- Medical University of Warsaw
- University of Hamburg
- University of Witten/Herdecke
- Uppsala University
- Department of Defense
- Cara Therapeutics
- Advanced Regenerative Medicine
- Rush University
- University of Erlangen-Nuremberg
- Moorgreen Hospital, Southampton
- IQVIA
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (9)
- Centre of Postgraduate Medical Education
- Katholieke Universiteit Leuven
- OhioHealth
- University of Colorado, Denver
- Medical Centre of Postgraduate Education, Poland
- Jiao Tong University
- The Medical Centre of Postgraduate Education, Department of Orthopaedics and Inflammatory Disorders of Locomotor System
- Department of Veteran Affairs
- Hope Biosciences